ÂÜÀòÂÒÂ×

Dr. Dennis Benjamin of Heceta Biosciences has over 20 years of experience in biotech and a deep expertise in therapeutics for oncology. He has discovered and helped develop platform technologies, bringing 25 molecules from discovery to IND and contributed to four FDA approvals. Prior to Heceta, Dennis spent 15 years at Seattle Genetics leading a 120-person department responsible for discovering and nominating IND candidates for company clinical pipeline.

Dennis holds a Bachelor of Science in Chemistry from the Massachusetts Institute of Technology and earned his Ph.D. in Medicinal Chemistry from the University of California San Francisco. He completed his Postdoctoral Fellowship at the University of Oxford. He has worked on nearly 30 publications during his long career.